Hence, a preponderance of publications on liver cancer in Africa focused on understanding the contribution of mutation and expression of TP53, and other tumor suppressors like TP73, RB, KLF6, and CTNNB1, to liver carcinogenesis (190, 192–207), particularly in Senegal, Gambia, Nigeria, South Africa, Egypt, and Morocco. Here, TP53 is linked to neoplasm.